Position paper of Italian rheumatologists on the use of biosimilar drugs

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 1-4

  Atzeni, Fabiola ^a   Sebastiani, Marco ^b   Ricci, Cristian ^c   Celano, Antonella ^d   Gremese, Elisa ^e   Iannone, Florenzo ^f   Meroni, Pier Luigi ^g   Minghetti, Paola ^g   Sarzi Puttini, Piercarlo ^a   Ferraccioli, Gianfranco ^e   Lapadula, Giovanni ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Association of Patients with Rheumatic Diseases Onlus ^*  (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

Biosimilar drugs; Clinical trials; Immunogenicity

Indexed keywords

BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; METHOTREXATE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG USE; GOLD STANDARD; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INFORMED CONSENT; ITALIAN (CITIZEN); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT INDICATION; CONSENSUS DEVELOPMENT; DRUG CONTROL; DRUG SUBSTITUTION; IMMUNOLOGY; ITALY; PATENT; PATIENT SAFETY; PRACTICE GUIDELINE; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTOR; STANDARDS; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG AND NARCOTIC CONTROL; DRUG SUBSTITUTION; HUMANS; INFORMED CONSENT; ITALY; PATENTS AS TOPIC; PATIENT SAFETY; RHEUMATIC DISEASES; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928705954     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. AIFA: Position paper. I farmaci biosimilari. 13/05/2013.
2. Biologics Price Competition and Innovation Act, BPCI Act SEC. 7002 b.
3. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Committee for Medicinal Products for Human Use (CHMP). EMEA/CHMP/BMWP/42832/2005, Rev. 1; 03 June May 2013.
4. PARK W1, HRYCAJ P, JEKA S et al.: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72: 1605-12.
5. van der HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
6. YOO DHL HRYCAJ P, MIRANDA P et al.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20.
7. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
8. WESTHOVENS R, YOCUM D, HAN J et al.: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075-86.
9. REICHERT JM: Next generation and bio-similar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany. MAbs 2011; 3: 223-40.
10. LEE H: Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?. AAPS J 2014; 16: 22-6.
11. World Health Organization: Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: World Health Organization; 2009.
12. UNGAR B, CHOWERS Y, YAVZORI M et al.: The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2013. doi:10.1136/gutjnl-2013-305259.
13. STRAND V, KIMBERLY R, ISAACS JD: Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6: 75-92.
14. PASCUAL-SALCEDO D, PLASENCIA C, RAMIRO S et al.: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis; Rheumatology 2011; 50: 1445-52.
15. TRUUS JANSE-de HOOG, Staff member MEBmeb: Interchangeability of generics. Zagreb, 14 June 2011.
16. DöRNER T, STRAND V, CASTAñEDA-HERNáNDEZ G et al.: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-8.
17. EMA Consensus Information Paper 2013: What you need to know about Biosimilar Medicinal Products.
18. LAPADULA G, FERRACCIOLI GF: Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 2012; 30: S102-6.